Kurzfassung

In collaboration with Phenex Pharmaceuticals AG (Ludwigshafen, Germany) we test and explore the function of newly developed RORγt-targeting compounds. RORγt is a transcription factor important for the differentiation of inflammatory Th17 cells thought to be important players in autoimmunity. Florian Kurschus is heading the project and together with co-workers he tests new lead-compounds in in vitro assays for Th17 differentiation as well as in in vivo assays in animal models for autoimmunity...In collaboration with Phenex Pharmaceuticals AG (Ludwigshafen, Germany) we test and explore the function of newly developed RORγt-targeting compounds. RORγt is a transcription factor important for the differentiation of inflammatory Th17 cells thought to be important players in autoimmunity. Florian Kurschus is heading the project and together with co-workers he tests new lead-compounds in in vitro assays for Th17 differentiation as well as in in vivo assays in animal models for autoimmunity and inflammation such as Multiple Sclerosis and Psoriasis. Many of the tested compounds indeed show a very good in vitro profile of specific inhibition of Th17 differentiation with low toxicity and several drugs were tested in vivo with very promising efficacy. We will further elaborate the function and of the RORγt targeting drugs in in vivo assays and in assays testing the inhibition of human Th17 responses.» weiterlesen» einklappen